Nigrosome 1 imaging: technical considerations and clinical applications.

A pathological study by Damier et al demonstrated that nigrosome 1, a dopaminergic neuron-rich region in the substantial nigra, is the most severely affected region in idiopathic Parkinson's disease. Since then, researchers have identified the location of nigrosome 1 in the dorsal aspect of the substantia nigra using susceptibility-weighted imaging in MRI. Although this observation was reconfirmed by various imaging techniques and imaging planes, non-standardized imaging methods may rather limit the generalized use of this imaging finding. The aim of this review is to revisit the anatomical definition of the nigrosome 1 region using high-spatial-resolution susceptibility map-weighted MRI in order to help the readers to determine the presence or absence of an abnormality in the nigrosome 1 region. Thereafter, we discuss the current status of nigrosome 1 imaging at 3 T and show how to improve the imaging quality for better assessment of nigrosome 1. We also illustrate the imaging findings of various patients who presented with parkinsonism, which can help the readers to learn how to use these images in practice. Lastly, we discuss potential future works with nigrosome 1 susceptibility map-weighted MRI.

[1]  Yoshiharu Tamakawa,et al.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.

[2]  B. Bloem,et al.  Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism , 2015, American Journal of Neuroradiology.

[3]  S. Kang,et al.  Loss of Substantia Nigra Hyperintensity at 3.0-T MR Imaging in Idiopathic REM Sleep Behavior Disorder: Comparison with 123I-FP-CIT SPECT. , 2017, Radiology.

[4]  N. Wang,et al.  Using ‘swallow-tail’ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson’s disease: A susceptibility-weighted imaging study , 2017, European Radiology.

[5]  J. J. Lee,et al.  Correlation of 3D FLAIR and Dopamine Transporter Imaging in Patients With Parkinsonism. , 2016, AJR. American journal of roentgenology.

[6]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[7]  R. Bowtell,et al.  Visualization of nigrosome 1 and its loss in PD , 2013, Neurology.

[8]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[9]  Z. Cho,et al.  Seven‐tesla magnetic resonance images of the substantia nigra in Parkinson disease , 2012, Annals of neurology.

[10]  Ji Young Yun,et al.  Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I‐FP‐CIT SPECT , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  D. Auer,et al.  Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3iPD study (nigrosomal iron imaging in Parkinson’s disease) , 2017, BMJ Open.

[12]  A. M. Ortiz,et al.  Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[13]  Martin Styner,et al.  Imaging nigral pathology and clinical progression in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[14]  A. Schnitzler,et al.  Manual MRI morphometry in Parkinsonian syndromes , 2017, Movement disorders : official journal of the Movement Disorder Society.

[15]  D. Jennings,et al.  Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.

[16]  E. Kim,et al.  Drug-induced Parkinsonism versus Idiopathic Parkinson Disease: Utility of Nigrosome 1 with 3-T Imaging. , 2016, Radiology.

[17]  P. Mir,et al.  Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Dorothee P Auer,et al.  In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. , 2017, Radiology.

[19]  Michael Schocke,et al.  Dorsolateral nigral hyperintensity on 3.0T susceptibility‐weighted imaging in neurodegenerative Parkinsonism , 2015, Movement disorders : official journal of the Movement Disorder Society.

[20]  T. Simuni,et al.  Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes? , 2017, Clinical imaging.

[21]  Dong-Hyun Kim,et al.  Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map‐weighted imaging (SMWI) , 2017, Journal of magnetic resonance imaging : JMRI.

[22]  Stanley Fahn,et al.  Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease , 2018, npj Parkinson's Disease.

[23]  A. van Cappellen van Walsum,et al.  Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson’s Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study , 2016, Polish journal of radiology.

[24]  W. Poewe,et al.  Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[25]  E. Kim,et al.  Initial diagnostic workup of parkinsonism: Dopamine transporter positron emission tomography versus susceptibility map-weighted imaging at 3T. , 2019, Parkinsonism & related disorders.

[26]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[27]  Dosik Hwang,et al.  Susceptibility map‐weighted imaging (SMWI) for neuroimaging , 2014, Magnetic resonance in medicine.

[28]  S. Gacinovic,et al.  Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]‐FP‐CIT SPECT imaging: The [123I]‐FP‐CIT study group , 2000, Movement disorders : official journal of the Movement Disorder Society.

[29]  F. Yang,et al.  Universality analysis of the existence of substantia nigra "swallow tail" appearance of non-Parkinson patients in 3T SWI. , 2016, European review for medical and pharmacological sciences.

[30]  J S Thornton,et al.  9.4T MR microscopy of the substantia nigra with pathological validation in controls and disease. , 2017, NeuroImage. Clinical.

[31]  Dorothee P. Auer,et al.  The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T , 2014, PloS one.

[32]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[33]  J. Rowe,et al.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[34]  R. Djaldetti,et al.  123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  Yasuo Terayama,et al.  Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.

[36]  Dorothee P Auer,et al.  T1‐Weighted MRI shows stage‐dependent substantia nigra signal loss in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[37]  Martin Styner,et al.  Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[38]  Eung Yeop Kim,et al.  Differential involvement of nigral subregions in idiopathic parkinson's disease , 2018, Human brain mapping.

[39]  J. Cummings,et al.  The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. , 2011, Brain : a journal of neurology.

[40]  A. Graybiel,et al.  The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. , 1999, Brain : a journal of neurology.

[41]  M. Tosetti,et al.  Comparison of 3T and 7T Susceptibility-Weighted Angiography of the Substantia Nigra in Diagnosing Parkinson Disease , 2015, American Journal of Neuroradiology.

[42]  D. Korzhevskii,et al.  Immunohistochemical Characteristics of Neurons in the Substantia Nigra of the Human Brain , 2018, Neuroscience and Behavioral Physiology.

[43]  W. Poewe,et al.  The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. , 2018, Parkinsonism & related disorders.

[44]  Francesco Fera,et al.  MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. , 2008, Radiology.

[45]  S. Fahn Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.

[46]  R. Mailman,et al.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients , 2018, Movement disorders : official journal of the Movement Disorder Society.

[47]  J. Lee,et al.  Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality , 2015, American Journal of Neuroradiology.

[48]  Xiangchuan Chen,et al.  A multicontrast approach for comprehensive imaging of substantia nigra , 2015, NeuroImage.